Carmela Cannavà

Dr. Carmela Cannavà


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2012 in Journal of Inclusion Phenomena and Macrocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
CCCarmela Cannavà
Carmela Cannavà
Vincenza CrupiVincenza Crupi
Vincenza Crupi
MGM. Guardo
M. Guardo
DMDomenico Majolino
Domenico Majolino
Rosanna StancanelliRosanna Stancanelli
Rosanna Stancanelli
Valentina VenutiValentina Venuti
Valentina Venuti

26 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
CCCarmela Cannavà
Carmela Cannavà
Federica De GaetanoFederica De Gaetano
Federica De Gaetano
Rosanna StancanelliRosanna Stancanelli
Rosanna Stancanelli
Valentina VenutiValentina Venuti
Valentina Venuti
Giuseppe PaladiniGiuseppe Paladini
Giuseppe Paladini
Cinzia Anna VenturaCinzia Anna Ventura
Cinzia Anna Ventura
In the present study, we developed chitosan/hyaluronan nanoparticles (CS/HY NPs) for tumor targeting with vinblastine sulfate (VBL), that can be directed to the CD44 transmembrane receptor, over-expressed in cancer cells. NPs were prepared by coating with HY-preformed chitosan/tripolyphosphate (CS/TPP) NPs, or by polyelectrolyte complexation of CS with HY. NPs with a mean hydrodynamic radius (RH) of 110 nm, 12% polydispersity index and negative zeta potential values were obtained by a direct complexation process. Transmission Electron Microscopy (TEM) images showed spherical NPs with a non-homogeneous matrix, probably due to a random localization of CS and HY interacting chains. The intermolecular interactions occurring between CS and HY upon NPs formation were experimentally evidenced by micro-Raman (µ-Raman) spectroscopy, through the analysis of the spectral changes of characteristic vibrational bands of HY during NP formation, in order to reveal the involvement of specific chemical groups in the process. Optimized NP formulation efficiently encapsulated VBL, producing a drug sustained release for 20 h. In vitro studies demonstrated a fast internalization of labeled CS/HY NPs (within 6 h) on K-562 human myeloid leukemia cells. Pre-saturation of CD44 by free HY produced a slowing-down of NP uptake over 24 h, demonstrating the need of CD44 for the internalization of HY-based NPs.